Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

MS trials. The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events. Eligible patients in this trial are now receiving dirucotide on an un-blinded basis to the end of their 27th month in the trial.

Licensing and Development Agreement with Lilly

On December 17, 2007, BioMS entered into a licensing and development agreement (the "Agreement") granting Lilly exclusive worldwide rights to dirucotide. The transaction closed on January 25, 2008 and BioMS received an upfront payment of US $87 million. In September 2008, BioMS received a development milestone payment of US $10 million as a result of the positive interim analysis from the DSMB for MASESTRO-01. BioMS has the potential to receive future development and sales milestones up to US $400 million and escalating royalties on sales if dirucotide is commercialized.

Not later than sixty (60) days following receipt of the final written report of the results of the MAESTRO-01 trial, Lilly shall notify BioMS in writing whether Lilly will terminate the Agreement or alternatively Lilly shall bear 100% of any and all continuing development costs incurred by Lilly or BioMS for dirucotide.

HYC750 and BioCyDex

On May 9, 2008, BioMS entered into a Royalty and Assignment Agreement with Orcrist Bio. Inc. for HYC750, a technology based on hyaluronic acid that has a number of potential therapeutic uses and is being developed as a treatment for the side effects of chemotherapy. BioMS held an exclusive worldwide license to HYC750 from the University of Alberta. As a result of the Royalty and Assignment Agreement, BioMS terminated its license with the University of Alberta and the University entered into
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... England , May 22, 2013 ... novel drug-only formulation of glycopyrronium bromide designed using Prosonix, ... pharmaceutical company developing a portfolio of inhaled Respiratory ... clinical study with PSX1002 that will assess its effect ... of doses in patients with moderate to severe chronic ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
(Date:5/21/2013)... 21, 2013 Clinverse, Inc. ... for clinical trials, announced today it has formed ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates ... SpendMD ™, Aggregate Spend Solutions’ recently-launched ... tracking and reporting transfer of value at investigator ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3
... 29, 2012  Dyadic International, Inc. ("Dyadic") (OTC Pink: ... discovery, development, manufacture and sale of enzyme and ... biopharmaceutical industries, announced today that it has entered ... a leading global provider of nutritional ingredient solutions ...
... the Wyss Institute for Biologically Inspired Engineering at Harvard ... for inducing magnetic sensitivity in an organism that is ... used to magnetize a variety of different cell types ... appear in today,s issue of PLoS Biology . ...
... 28, 2012  Thomson Reuters announced the availability of ... speeds access to critical life sciences research and ... platform, Thomson Reuters Cortellis. ... application programming interfaces (APIs) to enhance the research ...
Cached Biology Technology:Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes 2Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes 3New 'magnetic yeast' marks step toward harnessing Nature's magnetic capabilities 2New 'magnetic yeast' marks step toward harnessing Nature's magnetic capabilities 3Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services 2
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
(Date:5/22/2013)... feared Legionella pneumophila bacteria is responsible for ... In order to infect us, this pathogen has developed ... go unnoticed in our cells, thus avoiding these acting ... Basque biosciences research centre, CIC bioGUNE, in which teams ... USA and the National Supercomputation Centre in Barcelona (BSC) ...
(Date:5/22/2013)... in the biodiversity of pollinating insects and wild plants ... study. , Researchers led by the University of Leeds ... evidence of dramatic reductions in the diversity of ... 1950s and 1980s. , But the picture brightened markedly ... biodiversity losses among bees, hoverflies and wild plants. ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... fragments into a genome sequence that scientists can interpret is ... don,t have the box and have no idea what the ... DNA sequences of related organisms can be used to guide ... related any two sequences are to one another. For example, ...
... Radiology," the first in a series of annual ... invasive medicine, was recently released by Society of ... radiology is expanding, and it has become increasingly ... assimilate the volume of literature required to remain ...
... Scientists at the Salk Institute for Biological Studies and ... that play a role in the production of seed ... chemicals and biofuels. Scoring a rare scientific hat ... thale cress plants ( Arabidopsis thaliana ) that regulate ...
Cached Biology News:Researchers look to relatives for clues in quest to develop sources of bioenergy 2Researchers look to relatives for clues in quest to develop sources of bioenergy 3'Updates in Interventional Radiology' accents emerging trends, practice growth 2Discovery of plant proteins may boost agricultural yields and biofuel production 2Discovery of plant proteins may boost agricultural yields and biofuel production 3
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Biology Products: